Related Experiment Videos
miRNA-Mediated Signaling Networks in Non-Small Cell Lung Cancer: Linking Tumor Progression to Sarcopenia
Swati Goswami1,2, Pooja Gulhane1, Shailza Singh1,2
1Systems Medicine Laboratory, BRIC-National Centre for Cell Science, National Centre for Cell Science Complex, SPPU Campus, Ganeshkhind, Pune 411007, India.
Abstract:
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, with poor survival outcomes despite advances in surgery, chemotherapy, targeted therapy, and immunotherapy. The tumor microenvironment (TME) plays a central role in sustaining tumor growth, immune evasion, and systemic metabolic dysfunction. In this study, we performed an integrative analysis of differentially expressed microRNAs (miRNAs) to uncover their contributions to dysregulated signaling networks in NSCLC. hsa-miR-486-5p was identified as a prominent differentially expressed candidate miRNA. Using mathematical modeling and regression-based reduction, we identified Forkhead Box O1 (FOXO1) and Unc-51 like Autophagy Activating Kinase 2 (ULK2) as critical regulatory nodes that integrate oncogenic signaling with cellular homeostasis. Aberrant expression of hsa-miR-486-5p was found to modulate pathways including PI3K/AKT/mTOR, NF-κB, and JAK-STAT3, thereby promoting tumor progression and secretion of inflammatory cytokines. These cytokines, viz., IL-6, TNF-α, and IL-1β, activate muscle-specific protein degradation pathways through E3 ubiquitin ligases TRIM63 and FBXO32, linking NSCLC progression to cancer-associated sarcopenia. Quasipotential landscape analysis further revealed dynamic phenotypic transitions between stable and unstable states, highlighting the adaptability of tumor-host interactions. Collectively, our findings demonstrate that miRNA-mediated regulatory networks not only drive NSCLC progression and inflammation but also contribute to systemic muscle wasting. These insights emphasize the need for novel therapeutic strategies, including RNA-based interventions, to overcome resistance, improve survival, and address the metabolic complications associated with NSCLC.
Insights
This study reveals how microRNAs (miRNAs) drive non-small cell lung cancer (NSCLC) progression and inflammation, leading to muscle wasting. Novel RNA-based therapies could improve survival and metabolic health in NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Systems Biology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, with the tumor microenvironment (TME) crucial for tumor progression and immune evasion.
- Despite advances, NSCLC outcomes remain poor, necessitating deeper understanding of underlying molecular mechanisms.
- The TME influences systemic metabolism and immune responses, contributing to cancer-associated morbidity.
Purpose of the Study:
- To investigate the role of differentially expressed microRNAs (miRNAs) in NSCLC signaling networks using integrative analysis.
- To identify key regulatory nodes and pathways influenced by miRNAs in NSCLC pathogenesis.
- To explore the link between NSCLC progression, inflammation, and systemic metabolic dysfunction, specifically cancer-associated sarcopenia.
Main Methods:
- Integrative analysis of differentially expressed miRNAs in NSCLC.
- Mathematical modeling and regression-based reduction to identify regulatory nodes (FOXO1, ULK2).
- Analysis of modulated signaling pathways (PI3K/AKT/mTOR, NF-κB, JAK-STAT3) and cytokine secretion (IL-6, TNF-α, IL-1β).
- Investigation of E3 ubiquitin ligases (TRIM63, FBXO32) in muscle protein degradation.
- Quasipotential landscape analysis for dynamic phenotypic transitions.
Main Results:
- hsa-miR-486-5p identified as a key differentially expressed miRNA.
- FOXO1 and ULK2 identified as critical regulatory nodes integrating oncogenic signaling and homeostasis.
- Aberrant hsa-miR-486-5p expression modulates PI3K/AKT/mTOR, NF-κB, and JAK-STAT3 pathways, promoting tumor progression and inflammation.
- NSCLC-induced cytokines activate muscle-specific protein degradation via TRIM63 and FBXO32, linking cancer to sarcopenia.
- Dynamic phenotypic transitions observed, highlighting tumor-host interaction adaptability.
Conclusions:
- miRNA-mediated networks drive NSCLC progression, inflammation, and systemic muscle wasting (cancer-associated sarcopenia).
- Dysregulated miRNAs contribute to metabolic complications and poor survival in NSCLC.
- Novel therapeutic strategies, including RNA-based interventions, are needed to overcome resistance and improve patient outcomes.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MicroRNAs